<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100707004345N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-04-11</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>The effect of melatonin on anxiety before hysterectomy</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of melatonin on reducing preoperative anxiety in abdominal hysterectomy; a double blinded clinical trial study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-05-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/38635</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: To produce random sequences in this clinical trial, we will use this site: http://www.graphpad.com/quickcalcs/index.cfm. A nurse who is not in the study, 90 minutes before surgery, will randomly divide patients into two groups by quadruple block method that includes: lorazepam + melatonin( dissolved in 20 milliliters sugar water) group and  lorazepam+ sugar water group, Blinding description: A nurse who is not in the study randomly will divide patients into two groups and 90 minutes before surgery, for the intervention group, she will dissolve two melatonin pills in 20 milliliters of water. 2 sugar loaves will be added to it for not determining the taste. In the Control group, the same amount of sugar water is prescribed. After receiving the drug, the patient will be transferred to the recovery room and will be monitored to control blood pressure and heart rate. In this study, patients,  the responsible anesthesiologist, and the information collector are BLIND.</study_design>
      <phase>3</phase>
      <hc_freetext>Anxiety before abdominal hysterectomy  surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The group receiving lorazepam + Melatonin: Dosage of Melatonin for patients will be 6 milligrams based on previous studies. (3 milligrams tablets are available on the market, so two tablets are considered).(manufacturing Company: Aristo ).As the routine of this hospital is to prescribe 1miligramm lorazepam( manufacturing Company: Abidi)preoperative night for all patients candidate for hysterectomy, so both groups will receive this amount of lorazepam. (This treatment alone did not control anxiety in patients.)90 minutes Prior to surgery, a nurse who is not in the study will dissolve melatonin pills in 20 milliliters of water and will add 2 sugar loaves in order to not determine its taste. Intervention 2: Control group: The group receiving lorazepam + sugar water: preoperative night 1miligramm lorazepam( manufacturing Company: Abidi) will be given to patients.90 minutes prior to surgery,2 sugar loaves will be dissolved in 20 milliliters of water and it will be given to the patient by a nurse who is not in the study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is not decided yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Mirmansouri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Heshmat Hospital, at the beginning of bayani street, Mosalla Square</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654839</zip>
        <telephone>+98 13 1666 9064</telephone>
        <email>a_mirmansoori@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Mirmansouri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Heshmat Hospital, at the beginning of bayani street, Mosalla Square</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654839</zip>
        <telephone>+98 13 1666 9064</telephone>
        <email>a_mirmansoori@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Candidate for elective abdominal hysterectomy
Aged 30-65</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Major surgery for the past three years
Chronic health problems like diabetes, cardiovascular disease
Mood disorders (anxiety) that are under medication
Addiction
Malignant problems that cause hysterectomy
Emergency hysterectomy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F43</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Reaction to severe stress and adjustment disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The group receiving lorazepam + Melatonin: Dosage of Melatonin for patients will be 6 milligrams based on previous studies. (3 milligrams tablets are available on the market, so two tablets are considered).(manufacturing Company: Aristo ).As the routine of this hospital is to prescribe 1miligramm lorazepam( manufacturing Company: Abidi)preoperative night for all patients candidate for hysterectomy, so both groups will receive this amount of lorazepam. (This treatment alone did not control anxiety in patients.)90 minutes Prior to surgery, a nurse who is not in the study will dissolve melatonin pills in 20 milliliters of water and will add 2 sugar loaves in order to not determine its taste.</i_keyword>
      <i_keyword>Control group: The group receiving lorazepam + sugar water: preoperative night 1miligramm lorazepam( manufacturing Company: Abidi) will be given to patients.90 minutes prior to surgery,2 sugar loaves will be dissolved in 20 milliliters of water and it will be given to the patient by a nurse who is not in the study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Patient's anxiety before surgery. Timepoint: Before prescribing the drug, when patients enter the operating room and before the anesthetic induction. Method of measurement: Visual Aualogue scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Blood pressure. Timepoint: Before prescribing the drug, when patients enter the operating room and before the anesthetic induction. Method of measurement: Manometer.</sec_outcome>
      <sec_outcome>Heart rate. Timepoint: Before prescribing the drug, when patients enter the operating room and before the anesthetic induction. Method of measurement: Monitoring.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-03-16</approval_date>
        <contact_name>Ethics Committee Of Guilan University Of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for research, Shahid Siadati Avenue, Namjoo Street Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
